Dr. Eric D. Marsh, M.D.
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Neurology
Philadelphia, PA 19104
At a glance
- Medical school
- New York University School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
PA license MD073718L -
Clinical Neurophysiology Physician
PA license MD073718L -
Pediatrics Physician
PA license MD073718L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Health Care Associates Inc (220 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Epidiolex (cannabidiol (cbd)) | 26 |
| Daybue (trofinetide) | 23 |
| Briviact (brivaracetam) | 16 |
| Zonisamide Other prescribers in Philadelphia, PA | 15 |
| Onfi (clobazam) | 12 |
| Clonazepam Other prescribers in Philadelphia, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 30 payments worth $20,570 in total to this clinician.
| Acadia Pharmaceuticals Inc | $13,797 |
|---|---|
| UCB, Inc. | $3,060 |
| Jazz Pharmaceuticals Inc. | $2,284 |
| Ionis Pharmaceuticals, Inc. | $1,429 |
| Consulting Fee | $11,481 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,150 |
| Travel and Lodging | $2,057 |
| Food and Beverage | $881 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acadia Pharmaceuticals Inc Apr 23, 2025 | Consulting Fee DAYBUE · RETT SYNDROME | $5,700 |
| Acadia Pharmaceuticals Inc Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $5,700 |
| UCB, Inc. Dec 24, 2025 | Consulting Fee Fintepla · Neurology | $3,025 |
| Jazz Pharmaceuticals Inc. Jul 4, 2025 | Consulting Fee EPIDIOLEX · NEUROLOGY | $1,893 |
| Acadia Pharmaceuticals Inc Apr 1, 2025 | Consulting Fee DAYBUE · RETT SYNDROME · in-kind | $563 |
| Acadia Pharmaceuticals Inc Apr 1, 2025 | Travel and Lodging DAYBUE · RETT SYNDROME · travel to SAN DIEGO, CA · in-kind | $563 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $512 |
| Acadia Pharmaceuticals Inc Dec 29, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $450 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $342 |
| Jazz Pharmaceuticals Inc. Jul 4, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Philadelphia, PA · in-kind | $314 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Acadia Pharmaceuticals Inc Dec 29, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $450 |
| UCB, Inc. Dec 24, 2025 | Consulting Fee Fintepla · Neurology | $3,025 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $50.00 |
| Ionis Pharmaceuticals, Inc. Sep 19, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $45.00 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $512 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $342 |
| Ionis Pharmaceuticals, Inc. Sep 18, 2025 | Travel and Lodging travel to NASHVILLE, TN · in-kind | $149 |
| Jazz Pharmaceuticals Inc. Jul 4, 2025 | Consulting Fee EPIDIOLEX · NEUROLOGY | $1,893 |
| Jazz Pharmaceuticals Inc. Jul 4, 2025 | Travel and Lodging EPIDIOLEX · NEUROLOGY · travel to Philadelphia, PA · in-kind | $314 |
| Acadia Pharmaceuticals Inc Apr 23, 2025 | Consulting Fee DAYBUE · RETT SYNDROME | $5,700 |
| Acadia Pharmaceuticals Inc Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $5,700 |
| Acadia Pharmaceuticals Inc Apr 23, 2025 | Travel and Lodging DAYBUE · RETT SYNDROME · travel to SAN DIEGO, CA · in-kind | $82.60 |
| Acadia Pharmaceuticals Inc Apr 2, 2025 | Consulting Fee DAYBUE · RETT SYNDROME · in-kind | $150 |
| Acadia Pharmaceuticals Inc Apr 1, 2025 | Consulting Fee DAYBUE · RETT SYNDROME · in-kind | $563 |
| Acadia Pharmaceuticals Inc Apr 1, 2025 | Travel and Lodging DAYBUE · RETT SYNDROME · travel to SAN DIEGO, CA · in-kind | $563 |
| Acadia Pharmaceuticals Inc Apr 1, 2025 | Consulting Fee DAYBUE · RETT SYNDROME · in-kind | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $702,659 in research payments for these studies, mostly to the institutions running them.
- ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Ionis Pharmaceuticals, Inc. · Recruiting · NCT06430385 - Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Ionis Pharmaceuticals, Inc. · Terminated · NCT06014541 - Natural History study for MeCP2
Ionis Pharmaceuticals, Inc. - ION582P3
Ionis Pharmaceuticals, Inc. - YKP509C003
Sk Life Science, Inc. - A study of soticlestat as an add-on therapy in children and adults with dravet syndrome or lennox-gastaut syndrome
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
UCB SA · Recruiting · NCT07290036
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.